Article and Video CATEGORIES
Lyudmila A. Bazhenova, MD, is a board-certified medical oncologist. Her clinical practice is devoted to patients with all types of lung cancer, and she has particular expertise with female patients and nonsmokers. She believes in a multidisciplinary approach to lung cancer, and works closely with surgical oncologists and radiation oncologists to provide the best patient experience.
She leads a weekly "lung tumor board," where expert physicians and scientists from several specialties review cases to develop the best possible individualized treatment plan.
At our live event, Lung Cancer OncTalk 2023, Lyudmila Bazhenova talks about Antibody Drug Conjugates, Toxicities in Antibody Drug Conjugate Treatment, and Bispecific Antibodies in Lung Cancer.
To watch the complete playlist click here.
Please feel free to offer comments and raise questions in our
discussion forums.
Related Content
Forum Discussions
Hi elysianfields and welcome to Grace. I'm sorry to hear about your father's progression.
Unfortunately, lepto remains a difficult area to treat. Recently FDA approved the combo Lazertinib and Amivantamab...
Hello Janine, thank you for your reply.
Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...
Hi elysianfields,
That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...
Recent Comments
That's…